Shire plc News

Shire Plc : On Friday, Baird raised its price target on Shire following strong Q4 results.

Shire -- an Anglo-American specialist in hyperactivity and rare genetic diseases -- has been tipped as the hottest takeover target in the sector since French drugmaker Sanofi acquired U.S. biotech firm Genzyme early last year, a deal that showed there was appetite for rare disease drug specialists.

The Stoxx Europe 600 Index lost 0.9 percent to 261.24. The Stoxx 50 Index fell 0.9 percent to 2,468.05. The Euro Stoxx 50 Index, a benchmark measure for nations using the euro, declined 1.7 percent to 2,480.76. Alstom SA : The French company and Cofely Besix Facility Management said they won a 13-year contract worth 120 million euros from Dubai's ... (more)

Another Strong Year for Shire plc With Revenues Exceeding $4 Billion for the First Time and Non GAAP EPS up 26% to $5.34 Financial Highlights Full Year 2011 Product sales $3,950 million +26% Total revenues $4,263 million +23% Non GAAP operating income $1,357 million +27% US GAAP operating income $1,109 million +40% Non GAAP diluted earnings per ADS ... (more)

Shire PLC , the global specialty biopharmaceutical company, Thursday reported a rise in fourth quarter profit and said it looks forward to good earnings growth in 2012.

Shire plc Release: Vyvanse Capsules, Now Approved in the US for Maintenance Treatment in Adults with ADHD PHILADELPHIA, Feb.

Sangamo will also be entitled to certain milestone payments and royalties on sales from products developed through the partnership.

Sanofi's subsidiary Genzyme recently announced that it has received approval for the production of Fabrazyme at its Framingham manufacturing facility from the European Medicines Agency .